{"id":"https://openalex.org/W2586862487","doi":"https://doi.org/10.1200/jco.2012.30.27_suppl.110","title":"Interim safety results of eribulin (E) combined with ramucirumab (RAM) in patients (pts) with advanced metastatic breast cancer (MBC).","display_name":"Interim safety results of eribulin (E) combined with ramucirumab (RAM) in patients (pts) with advanced metastatic breast cancer (MBC).","publication_year":2012,"publication_date":"2012-09-20","ids":{"openalex":"https://openalex.org/W2586862487","doi":"https://doi.org/10.1200/jco.2012.30.27_suppl.110","mag":"2586862487"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2012.30.27_suppl.110","doi":"https://doi.org/10.1200/jco.2012.30.27_suppl.110","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2012.30.27_suppl.110","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5022422153","display_name":"Denise Aysel Yardley","orcid":"https://orcid.org/0000-0002-8664-3458","observed_orcids":["https://orcid.org/0000-0002-8664-3458","https://orcid.org/0009-0008-1720-6183"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Denise Aysel Yardley","raw_affiliation_strings":["Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079509906","display_name":"Cynthia R. C. Osborne","orcid":"https://orcid.org/0000-0001-8040-4985","observed_orcids":["https://orcid.org/0000-0001-8040-4985"]},"institutions":[{"id":"https://openalex.org/I2800124591","display_name":"Texas Oncology","ror":"https://ror.org/02ketev28","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800124591"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cynthia R. C. Osborne","raw_affiliation_strings":["Baylor Sammons Cancer Center, Texas Oncology PA, Dallas, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Baylor Sammons Cancer Center, Texas Oncology PA, Dallas, TX","institution_ids":["https://openalex.org/I2800124591"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017228186","display_name":"Paul D. Richards","orcid":"https://orcid.org/0000-0002-0320-9083","observed_orcids":["https://orcid.org/0000-0002-0320-9083"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul D. Richards","raw_affiliation_strings":["Oncology and Hematology Associates of Southwest Virginia, Salem, VA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology and Hematology Associates of Southwest Virginia, Salem, VA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109178293","display_name":"Brooke R. Daniel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brooke R. Daniel","raw_affiliation_strings":["Chattanooga Oncology and Hematology Associates, Chattanooga, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chattanooga Oncology and Hematology Associates, Chattanooga, TN","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110975690","display_name":"Michael A. Danso","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210088931","display_name":"Virginia Oncology Associates","ror":"https://ror.org/009yyqs39","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210088931"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael A. Danso","raw_affiliation_strings":["Virginia Oncology Associates, Norfolk, VA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virginia Oncology Associates, Norfolk, VA","institution_ids":["https://openalex.org/I4210088931"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076486609","display_name":"Anne M. Favret","orcid":"https://orcid.org/0000-0002-7917-5238","observed_orcids":["https://orcid.org/0000-0002-7917-5238"]},"institutions":[{"id":"https://openalex.org/I4210122908","display_name":"Virginia Cancer Specialists","ror":"https://ror.org/03tbabt10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210122908"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anne Favret","raw_affiliation_strings":["Virginia Cancer Specialists, PC, Fairfax, VA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Virginia Cancer Specialists, PC, Fairfax, VA","institution_ids":["https://openalex.org/I4210122908"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000035636","display_name":"Jane L. Bromund","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jane Bromund","raw_affiliation_strings":["Eli Lilly and Company, Indianapolis, IN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Eli Lilly and Company, Indianapolis, IN","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110584250","display_name":"Yanzhi Hsu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yanzhi Hsu","raw_affiliation_strings":["ImClone Systems Corporation, a wholly owned subsidiary of Eli Lilly and Company, Bridgewater, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImClone Systems Corporation, a wholly owned subsidiary of Eli Lilly and Company, Bridgewater, NJ","institution_ids":["https://openalex.org/I168537998"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112266428","display_name":"Ayman B. Ibrahim","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I168537998","display_name":"Eli Lilly (United States)","ror":"https://ror.org/01qat3289","country_code":"US","type":"company","lineage":["https://openalex.org/I168537998"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ayman B. Ibrahim","raw_affiliation_strings":["ImClone Systems Corporation, a wholly owned subsidiary of Eli Lilly and Company, Bridgewater, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ImClone Systems Corporation, a wholly owned subsidiary of Eli Lilly and Company, Bridgewater, NJ","institution_ids":["https://openalex.org/I168537998"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"30","issue":"27_suppl","first_page":"110","last_page":"110"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.8179000020027161,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.8179000020027161,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.15860000252723694,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.011699999682605267,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/eribulin","display_name":"eribulin","score":0.9760000109672546},{"id":"https://openalex.org/keywords/ramucirumab","display_name":"ramucirumab","score":1.0},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.8730000257492065},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5299999713897705},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.722000002861023},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8299999833106995},{"id":"https://openalex.org/keywords/vegfr-2-inhibition","display_name":"VEGFR-2 inhibition","score":0.7680000066757202},{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.8629999756813049},{"id":"https://openalex.org/keywords/microtubule-inhibitors","display_name":"microtubule inhibitors","score":0.7870000004768372},{"id":"https://openalex.org/keywords/febrile-neutropenia","display_name":"febrile neutropenia","score":0.8379999995231628},{"id":"https://openalex.org/keywords/third-line-therapy","display_name":"third-line therapy","score":0.5440000295639038},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.625},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.7419999837875366},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.9760000109672546},{"id":"https://openalex.org/keywords/dose-intensity","display_name":"dose intensity","score":0.30300000309944153}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.905646800994873},{"id":"https://openalex.org/C2776387010","wikidata":"https://www.wikidata.org/wiki/Q408717","display_name":"Eribulin","level":5,"score":0.828855037689209},{"id":"https://openalex.org/C2777511904","wikidata":"https://www.wikidata.org/wiki/Q425227","display_name":"Taxane","level":4,"score":0.7316362261772156},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.6307933330535889},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6257177591323853},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5159200429916382},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.5071578025817871},{"id":"https://openalex.org/C2776802502","wikidata":"https://www.wikidata.org/wiki/Q417589","display_name":"Anthracycline","level":4,"score":0.500816822052002},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.4972837269306183},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.4386041462421417},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.4362223446369171},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4292279779911041},{"id":"https://openalex.org/C61943457","wikidata":"https://www.wikidata.org/wiki/Q6046661","display_name":"Interim analysis","level":3,"score":0.4203023910522461},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.41910409927368164},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4162779450416565},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.41001763939857483},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.35835176706314087},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.14844253659248352}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2012.30.27_suppl.110","doi":"https://doi.org/10.1200/jco.2012.30.27_suppl.110","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2012.30.27_suppl.110","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2602803086","https://openalex.org/W2484150980","https://openalex.org/W2021264260","https://openalex.org/W7095742268","https://openalex.org/W4387585723","https://openalex.org/W2591046956","https://openalex.org/W2768302784","https://openalex.org/W2567887715","https://openalex.org/W2513941050","https://openalex.org/W2741748273"],"abstract_inverted_index":{"110":[0],"Background:":[1],"VEGF-mediated":[2],"angiogenesis":[3],"contributes":[4],"to":[5,82,132,195,275,304],"breast":[6],"cancer":[7],"(BC)":[8],"pathogenesis.":[9],"RAM":[10,81,143,262],"(IMC-1121B),":[11],"a":[12,53,73,251],"fully":[13],"human":[14],"IgG1":[15],"monoclonal":[16],"antibody":[17],"(MAb),":[18],"targets":[19],"VEGFR-2,":[20],"blocking":[21],"the":[22,197,277,285,308],"interaction":[23],"of":[24,80,95,108,182,190,207,287],"VEGF":[25],"ligands":[26],"and":[27,36,44,72,124,155,160,166,186,216,247,253,300],"VEGFR\u20112.":[28],"DC101":[29],"(murine":[30],"anti-VEGFR-2":[31],"MAb)":[32],"impairs":[33],"vascular":[34],"function":[35],"increases":[37],"tumor":[38,46],"hypoxia":[39],"in":[40,48,59,88,92,98,237],"xenograft":[41],"BC":[42],"models":[43],"inhibits":[45],"growth":[47],"cytotoxic-resistant":[49],"models.":[50],"E":[51,83,136,185],"is":[52,76,112,203],"novel":[54],"non-taxane":[55],"microtubule":[56],"inhibitor":[57],"indicated":[58],"MBC":[60,89,120],"pts":[61,175],"who":[62],"have":[63,162],"received":[64,179,255],"\u22652":[65],"prior":[66,126,156,194],"chemotherapy":[67,127],"regimens,":[68],"including":[69],"an":[70,93,109,290],"anthracycline":[71],"taxane.":[74],"It":[75],"hypothesized":[77],"that":[78],"addition":[79],"as":[84],"3rd-5th":[85],"line":[86],"therapy":[87,158,191],"will":[90],"result":[91],"improvement":[94],"median":[96],"PFS":[97],"this":[99],"ongoing,":[100],"multicenter,":[101],"US":[102],"study.":[103],"A":[104],"planned":[105,297],"safety":[106,271,299],"analysis":[107],"initial":[110,198],"cohort":[111],"reported.":[113,269],"Methods:":[114],"Pts":[115,150],"with":[116,296],"locally":[117],"recurrent":[118],"or":[119,122,135,184],"(HER2+":[121],"HER2-)":[123],"2-4":[125],"regimens":[128],"are":[129,151,268],"randomized":[130],"1:1":[131],"receive":[133],"RAM+E":[134,183,241,288],"(E":[137,258],"1.4":[138],"mg/m2":[139],"Days":[140],"1,":[141],"8;":[142],"10":[144],"mg/kg":[145],"Day":[146],"1;":[147],"q21":[148],"days).":[149],"stratified":[152],"by":[153],"TNBC":[154],"antiangiogenic":[157],"status":[159],"must":[161],"ECOG":[163],"PS":[164],"0-1":[165],"normal":[167],"LVEF.":[168],"Planned":[169],"accrual:":[170],"134":[171],"pts.":[172],"Results:":[173],"Evaluable":[174],"(n=13,":[176],"8":[177,264],"RAM+E)":[178],"\u22651":[180],"dose":[181,301],"completed":[187],"2":[188,199],"cycles":[189],"(or":[192],"discontinued":[193],"completing":[196],"cycles).":[200],"Median":[201],"age":[202],"55":[204],"yrs.":[205],"Assessment":[206],"adverse":[208],"events":[209],"(all":[210],"cause)":[211],"revealed":[212],"nausea,":[213],"fatigue,":[214],"headache,":[215],"neutropenia":[217,246],"were":[218],"more":[219,225],"frequent":[220,226],"for":[221,227,234],"RAM+E;":[222],"anemia":[223],"was":[224,232],"E.":[228],"G1":[229],"sensory":[230],"neuropathy":[231],"reported":[233],"1":[235],"pt":[236,242],"each":[238],"arm.":[239],"One":[240],"experienced":[243],"G3":[244],"febrile":[245],"odynophagia,":[248],"recovered":[249],"within":[250],"week,":[252],"subsequently":[254],"reduced":[256],"dosage":[257],"=":[259,263],"1.1":[260],"mg/m2;":[261],"mg/kg).":[265],"No":[266],"deaths":[267],"The":[270],"assessment":[272],"committee":[273],"recommended":[274],"continue":[276],"trial":[278],"unmodified.":[279],"Conclusions:":[280],"Based":[281],"on":[282],"preliminary":[283],"data,":[284],"combination":[286],"demonstrates":[289],"acceptable":[291],"toxicity":[292],"profile.":[293],"Accrual":[294],"continues,":[295],"updated":[298],"intensity":[302],"data":[303],"be":[305],"presented":[306],"at":[307],"meeting.":[309],"[Table:":[310],"see":[311],"text]":[312]},"counts_by_year":[{"year":2014,"cited_by_count":2}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2017-02-17T00:00:00"}